ESTIMATED
(AS OF MARCH 31)
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 03/14/2024 | Q3 2024 | -$0.03 | $14,700 | 12/14/2023 | Q2 2024 | -$0.16 | $3,900 | 09/14/2023 | Q1 2024 | -$0.13 | $0 | 07/18/2023 | Q4 2023 | -$0.16 | $5.14 M | 03/16/2023 | Q3 2023 | -$0.16 | $1,950 | 12/15/2022 | Q2 2023 | -$0.22 | $0 | 09/12/2022 | Q1 2023 | -$0.31 | $3,200 | 07/29/2022 | Q4 2022 | -$0.64 | $4,149 | 01/31/2022 | Q3 2022 | -$0.15 | $2,740 | 10/30/2021 | Q2 2022 | -$0.13 | $0 | 07/30/2021 | Q1 2022 | -$0.06 | $7,484 | 04/29/2021 | Q4 2021 | -$0.11 | $14,950 |
---|
A. Heart Test Laboratories, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, January 30th, 2023 based off last year's report dates.
A. The conference call for Heart Test Laboratories, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Heart Test Laboratories, Inc.'s latest earnings report can be read online.
A. Heart Test Laboratories, Inc. (NASDAQ:HSCSW) has a recorded annual revenue of $5,150.
A. Heart Test Laboratories, Inc. (NASDAQ:HSCSW) has a recorded net income of $5,150. Heart Test Laboratories, Inc. has generated $-61.74 earnings per share over the last four quarters.
A. Heart Test Laboratories, Inc. (NASDAQ:HSCSW) has a price-to-earnings ratio of -38.09 and price/earnings-to-growth ratio is 0.